Losec Mups 10 mg Noruega - noruec - Statens legemiddelverk

losec mups 10 mg

cheplapharm arzneimittel gmbh - omeprazolmagnesium - enterotablett - 10 mg

Losec Mups 20 mg Noruega - noruec - Statens legemiddelverk

losec mups 20 mg

cheplapharm arzneimittel gmbh - omeprazolmagnesium - enterotablett - 20 mg

Lariam 250 mg Noruega - noruec - Statens legemiddelverk

lariam 250 mg

cheplapharm arzneimittel gmbh - meflokinhydroklorid - tablett - 250 mg

Vepesid 50 mg Noruega - noruec - Statens legemiddelverk

vepesid 50 mg

cheplapharm arzneimittel gmbh - etoposid - kapsel, myk - 50 mg

CoAprovel 300 mg / 25 mg Noruega - noruec - Statens legemiddelverk

coaprovel 300 mg / 25 mg

orifarm as - irbesartan / hydroklortiazid - tablett - 300 mg / 25 mg

Brukinsa Unió Europea - noruec - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Toujeo 300 E/ ml Noruega - noruec - Statens legemiddelverk

toujeo 300 e/ ml

orifarm as - insulin glargin - injeksjonsvæske, oppløsning i ferdigfylt penn - 300 e/ ml

Tukysa Unió Europea - noruec - EMA (European Medicines Agency)

tukysa

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiske midler - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Vyvgart Unió Europea - noruec - EMA (European Medicines Agency)

vyvgart

argenx - efgartigimod alfa - myasthenia gravis - immunsuppressive - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Aldurazyme Unió Europea - noruec - EMA (European Medicines Agency)

aldurazyme

sanofi b.v. - laronidase - mukopolysakkaridose i - andre alimentary tract and metabolism products, - aldurazyme er indikert for langsiktig enzym erstatning terapi hos pasienter med en bekreftet diagnose av mucopolysaccharidosis jeg (mps jeg; alfa-l-iduronidase mangel på) til å behandle nonneurological manifestasjoner av sykdommen.